Yoshida T, Nakamura S, Ohtake S, Kobayashi K, Kanno M, Matsuda T, Matano S, Kondo K, Okafuji K, Kanai M
Third Department of Internal Medicine, Kanazawa University School of Medicine, Japan.
Cancer Chemother Pharmacol. 1989;25(2):135-8. doi: 10.1007/BF00692354.
A total of 40 patients with recurrent non-Hodgkin's lymphoma were treated with ABEP combination chemotherapy (aclarubicin, N4-behenoyl-1-beta-D-arabinofuranosylcytosine, etoposide, and prednisolone). A complete remission (CR) was achieved in 37.5% of the patients and partial remission, in 15.0%. The ABEP regimen proved to be effective in T-cell as well as B-cell lymphoma. It appears that the ABEP regimen may be partially non-cross-resistant with front-line doxorubicin-containing combinations. Survival for 39 months was achieved in 42.0% of the CR responders compared with 6.7% of partial responders (PRs) and nonresponders (NRs) (P less than 0.01). Disease-free survival for 45 months was seen in 66% of the CR patients. The ABEP regimen was effective in the treatment of patients with recurrent or refractory lymphoma, enabling hope for long-term survival in the majority of CR cases.
共有40例复发性非霍奇金淋巴瘤患者接受了ABEP联合化疗（阿克拉霉素、N4-二十二烷酰-1-β-D-阿拉伯呋喃糖基胞嘧啶、依托泊苷和泼尼松龙）。37.5%的患者实现了完全缓解（CR），15.0%的患者实现了部分缓解。ABEP方案在T细胞淋巴瘤和B细胞淋巴瘤中均被证明有效。ABEP方案似乎与含一线阿霉素的联合方案有部分非交叉耐药性。CR反应者中有42.0%存活39个月，而部分反应者（PR）和无反应者（NR）中这一比例为6.7%（P<0.01）。66%的CR患者无病生存期达45个月。ABEP方案对复发性或难治性淋巴瘤患者的治疗有效，使大多数CR病例有长期生存的希望。
